What Happens If China Controls the Next Cure?

For most of modern history, if a drug mattered, it was developed in the United States.

That wasn’t an accident. It was the result of a system we built deliberately: world-class universities, deep capital markets, strong patent protections, and a regulatory framework that—while slow and expensive—set the global standard for what “safe and effective” actually means.

That system still exists. It’s just no longer the only one that matters.

A new study published in JAMA last week put numbers to something that’s been quietly building for years.

Global drug development has nearly doubled over the past decade. The United States is still growing—but modestly. China, on the other hand, has gone from roughly 800 drug development programs to more than 6,000. In that same period, America’s share of global development dropped from about half to just over a third.

That’s not a blip. That’s a structural shift.

And it’s not just volume.

For years, the narrative around China’s pharmaceutical industry was simple: copy what works in the West, manufacture it cheaper, and scale it domestically. That narrative is outdated. Today, China is competing in some of the most advanced areas of medicine—cancer therapies, biologics, cell and gene treatments—and in some cases, doing it at a comparable level of sophistication.

They’re also doing it faster.

According to industry data cited in the same JAMA editorial, early-stage clinical trials in China are completed roughly 50% faster and at a fraction of the cost of those in the United States.

That’s the part that should make you pause.

Because this isn’t about intelligence, or talent, or even scientific capability.

It’s about economics.

The United States still has the most rigorous drug development system in the world. That’s something we should be proud of, and it’s something worth protecting. The FDA approval process is not a bug in the system—it is the system. It’s the reason patients can trust that when a drug hits the market. It has been tested, scrutinized, and challenged from every angle.

But that rigor comes at a cost.

Drug development in the U.S. is slow. It’s expensive. And increasingly, it’s being outcompeted by systems that are simply more efficient.

China has built a parallel model—one that still follows the broad contours of modern drug development, but operates with lower costs, faster timelines, and a regulatory environment designed to accelerate progress rather than slow it down.

Put simply:

The United States built the gold standard.

China is building the faster version of it.

And for the first time, speed might matter just as much as perfection.

Now, to be clear: more drug development anywhere in the world is a good thing.

More competition means more shots on goal. More shots on goal means more breakthroughs. If new therapies are discovered faster and brought to market more efficiently, patients everywhere benefit.

But that’s only half the story.

Medicine isn’t just about innovation. It’s about control.

For decades, the United States hasn’t just led drug development—we’ve defined it.

We’ve decided what gets studied, how it gets studied, and what standard of evidence is required before it reaches patients. We’ve controlled the early stages of the pipeline, where the most important decisions are made.

That control is starting to shift.

More early-stage trials are launching in China. More data is being generated there. And increasingly, there are scenarios where a drug might be developed, tested, and even approved in one region before the United States has meaningfully participated at all.

That creates a new reality.

One where access to cutting-edge therapies doesn’t just depend on science—it depends on coordination.

On data sharing.

On regulatory alignment.

On cooperation between governments that don’t always cooperate.

We’ve already seen what happens when critical parts of the drug supply chain move overseas.

Today, the vast majority of active pharmaceutical ingredients—the core components of most medications—are manufactured outside the United States, largely in China and India. That system works… until it doesn’t.

Now imagine that same dynamic applied not just to manufacturing, but to innovation itself.

Imagine the next breakthrough cancer therapy is developed, tested, and scaled primarily in China.

Or the next generation of weight-loss drugs.

Or, more realistically, the next pandemic vaccine.

In a world where geopolitical relationships are stable, that’s manageable.

In a world where they’re not, it’s a problem.

Let’s call it like it is.

The worst-case scenario isn’t that China develops more drugs than we do.

The worst-case scenario is that a global health crisis emerges—a new virus, a new pathogen, something we can’t predict—and the fastest or most effective solution is controlled by a country we are not on good terms with.

That’s not a conspiracy theory.

It’s just a logical extension of the trend.

And if that happens, access becomes a negotiation.

Not a guarantee.

There are also real scientific questions that come with this shift.

Clinical trials conducted in a largely homogenous population don’t always translate cleanly to a country as diverse as the United States. Differences in genetics, metabolism, and disease prevalence can materially affect how drugs perform across populations.

That’s why regulators talk about “bridging studies”—additional trials designed to confirm that results observed in one region apply to another. In practice, this would mean that a drug fully developed “soup-to-nuts” in China would have to undergo additional trials to determine safety and efficacy for the U.S. population.

Those safeguards matter.

And they’re one of the reasons the FDA process exists in the first place.

But they also introduce friction.

Time.

Cost.

The very things that are now being competed on globally.

So where does that leave us?

This didn’t happen because China cheated.

It happened because they built a system optimized for speed and cost—two variables that increasingly define modern drug development.

And on our side, the issue isn’t scientific capability.

It’s policy.

The United States has made it extraordinarily expensive to develop drugs. We’ve layered complexity on top of complexity, slowed timelines, and created a system where only the largest companies can afford to play at scale.

At the same time, we’ve turned “Big Pharma” into a political punching bag—ignoring the uncomfortable truth that those profits, patents, and incentives are the very things that fund the next generation of medicine.

You can’t demand breakthrough innovation and then strip away the incentives that make it possible.

It doesn’t work.

The good news is this is fixable.

We don’t need to lower our standards.

We don’t need to cut corners on safety.

But we do need to take a hard look at the economics of drug development in this country.

That means:

Creating stronger financial incentives for early-stage research.

Making it easier—not riskier, but easier—to run clinical trials domestically.

And recognizing that maintaining leadership in medicine isn’t just about science.

It’s about strategy.

Because here’s the reality:

The next generation of life-changing drugs will almost certainly still be sold in America.

But they may not be discovered here.

And if that happens, we’re not just buying medicine.

We’re asking for it.

Giddy up.

Alec Wade Ginsberg, PharmD, RPh
4th-Gen Pharmacist | Owner & COO, C.O. Bigelow
Founder, Drugstore Cowboy